

Product Licence Number	Company Name	Product Name	Active Ingredients	Indications	Date of Authorisation
		1-1% Amino Acids	L-Tryptophan FRP-027% w/v L-Phenylalanine USP-057% w/v L-Threonine USP-0646% w/v L-Serine USP-051% w/v L-Proline USP-0595% w/v Glycine USP-051% w/v L-Alanine USP-0551% w/v L-Valine USP-1393% w/v L-Methionine USP-083% w/v L-Isoleucine USP-083% w/v L-Leucine USP-102% w/v L-Lysine (Hydrochloride) USP-0955% w/v L-Histidine USP-0714% w/v L-Arginine USP-1071% w/v Calcium Chloride EP-0184% w/v Magnesium Chloride EP-0051% w/v Sodium Lactate FRP-448% w/v Sodium Chloride EP-538% w/v Bendrofluazide EP 2-50 mg		
0142/0380	A. H. Cox and Company Limited t/a Cox Pharmaceuticals	Bendrofluazide Tablets BP 2-5 mg	Bendrofluazide EP 2-50 mg	Cases where the reduction of fluid retention by diuresis is required; Oedema of cardiac, renal or hepatic origin; premenstrual oedema; Toxaemia of pregnancy, Iatrogenic oedema and all other types of oedema. Bendrofluazide produces a moderate but usefully prolonged fall of blood pressure in hypertensive patients. It may be used as a sole antihypertensive agent, or, as an adjunct to other drugs whose action it potentiates; suppression of lactation. POM (See PL/0142/0380).	27th June 1994
0142/0381	A. H. Cox and Company Limited t/a Cox Pharmaceuticals	Bendrofluazide Tablets BP 5 mg	Bendrofluazide EP 5-00 mg		27th June 1994
0201/0169	Schering-Plough Limited	Cedax Capsules 200 mg	Ceftibuten HSE 200 mg	Pharyngitis, tonsillitis in adults and/or children; otitis media in children. Acute episodes of bronchitis and acute exacerbations of chronic bronchitis in adults. <i>Urinary Tract Infections</i> , in adults and children, both complicated and uncomplicated infections. POM (See PL/0201/0169).	13th April 1994
0201/0170	Schering-Plough Limited	Cedax Capsules 400 mg	Ceftibuten HSE 400 mg		13th April 1994
0201/0171	Schering-Plough Limited	Cedax Powder for Oral Suspension 90 mg per 5 ml	Ceftibuten HSE 90 mg		13th April 1994
0201/0172	Schering-Plough Limited	Cedax Powder for Oral Suspension 180 mg per 5 ml	Ceftibuten HSE 180 mg		13th April 1994
00242/0197	Janssen Pharmaceutical Limited	Sporanox Capsules 100 mg	Itracozazole HSE 100 mg	Onychomycosis caused by dermatophytes and/or yeasts. POM	29th April 1994
0289/0291	Approved Prescription Services Limited	Timpron EC Tablets 375 mg Naproxen EC Tablets 375 mg	Naproxen BP 375-0 mg	For the treatment of pain and inflammation in rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, musculoskeletal disorders, low back pain and any severe periarticular disorders such as bursitis, tendinitis, synovitis, tenosynovitis, capsulitis, gout and dysmenorrhoea. POM (See PL/0289/0291).	19th April 1994
0289/0292	Approved Prescription Services Limited	Timpron EC Tablets 500 mg Naproxen EC Tablets 500 mg	Naproxen BP 500-0 mg		19th April 1994
2848/0178	Antigen International Limited	Bupivacaine Hydrochloride Injection BP 0-25% w/v	Bupivacaine Hydrochloride BP 0-264% w/v equivalent to Anhydrous Bupivacaine Hydrochloride 0-25% w/v	Surgical operations, including obstetric operations such as caesarean section; acute pain relief, including labour or postoperative pain; diagnosis and treatment of chronic pain, e.g. sympathetic nerve blocks. Bupivacaine can be used for different anaesthetic techniques including local infiltration, minor and major nerve blocks and epidural blockade. POM (See PL/2848/0178)	22nd June 1994
2848/0179	Antigen International Limited	Bupivacaine Hydrochloride Injection BP 0-5% w/v	Bupivacaine Hydrochloride BP 0-527% w/v equivalent to Anhydrous Bupivacaine Hydrochloride 0-5% w/v		22nd April 1994
3194/0046	Ferring Pharmaceuticals Limited	Demotabs 0-2 mg	Demopressin Acetate HSE 0-20 mg	Treatment of Vasopressin-sensitive cranial diabetes insipidus or post-hypophysectomy polyuria/polydipsia and primary nocturnal Enuresis. POM	19th April 1994
3524/0021	Organon Teknika Limited	Esmeron	Rocuronium Bromide HSE 10-00 mg	As an adjunct to general anaesthesia to facilitate endotracheal intubation, to provide skeletal muscle relaxation, and to facilitate mechanical ventilation. POM	6th April 1994
4425/0125	Marion Merrell Dow Limited	Calceol Tablets 6 mg	Deflazacort HSE 6-0 mg	Anaphylaxis, asthma, severe hypersensitivity reactions; rheumatoid arthritis, juvenile chronic arthritis, polymyalgia rheumatica systemic lupus erythematosus, dermatomyositis, mixed connective tissue disease (other than systemic sclerosis), polyarthritis nodosa; sarcoidosis; pemphigus, bullous pemphigoid, pyoderma gangrenosum; minimal change nephrotic syndrome, acute interstitial nephritis; rheumatic carditis; ulcerative colitis, Crohn's disease; uveitis, optic neuritis; autoimmune haemolytic anaemia, idiopathic thrombocytopenic purpura,	28th April 1994